Purity and Identity Testing of API Pharmaceutical

Photo: Trnava University / Unsplash

The production of pharmaceuticals requires absolute certainty regarding the quality of the raw materials used, especially active substances. Even a minor deviation in purity or incorrect identification can lead to serious issues – from reduced drug efficacy to the risk of contamination. Therefore, testing the purity and identity of pharmaceutical raw materials is an essential part of every production process. In this article, we will explore the standard methods used in practice and how to correctly interpret the results of analyses. We will also focus on common mistakes when selecting suppliers and which documents should be part of every delivery.

Why is testing the purity and identity of pharmaceutical raw materials crucial?

Testing the purity and identity of active pharmaceutical ingredients (APIs) is a fundamental prerequisite for ensuring the safety, efficacy, and quality of medicinal products. Even minor deviations in purity or incorrect identification can lead to serious health risks, reduced therapeutic effect, or even production waste. According to REACH regulations and the guidelines of the European Medicines Agency (EMA), every batch of raw material must undergo rigorous testing to confirm its compliance with specifications. This applies not only to final medicinal products but also to intermediates and input raw materials.

In practice, testing focuses on the detection of impurities such as residual solvents, heavy metals, microbial contamination, or degradation products. The identity of the substance is verified using spectroscopic methods (e.g., infrared spectroscopy, nuclear magnetic resonance) and chromatographic techniques (HPLC, GC). These analyses must be performed according to standard operating procedures (SOPs) and validated methods to ensure that the results are reproducible and legally defensible.

What methods are used to verify the identity of active substances?

The identity of a pharmaceutical raw material is verified using a combination of several analytical methods that provide a comprehensive picture of the substance’s structure and composition. The basic technique is infrared spectroscopy (IR), which identifies functional groups and characteristic bonds in the molecule. For more precise structural determination, nuclear magnetic resonance (NMR) is often used, as it distinguishes individual atoms and their chemical environment. For optically active substances, polarimetry is essential, as it measures the specific angle of rotation of the plane of polarized light.

Another key method is mass spectrometry (MS), often combined with liquid chromatography (LC-MS), which allows the identification of even minor components in a mixture. To confirm identity, X-ray diffraction (XRD) is also used, particularly for crystalline substances where it is important to verify the polymorphic form. All these methods must be calibrated and validated according to current pharmaceutical standards to ensure that the results are reliable and acceptable to regulatory authorities.

Photo: Julia Koblitz / Unsplash

How is purity testing and impurity detection carried out?

Testing the purity of pharmaceutical raw materials involves quantitative analysis of the main substance content and detection of any impurities. High-performance liquid chromatography (HPLC) is most commonly used, as it separates individual components of the mixture and enables their precise determination. For volatile impurities, such as residual solvents, gas chromatography (GC) with an FID detector or mass spectrometer is suitable. Heavy metals are determined using atomic absorption spectrometry (AAS) or inductively coupled plasma mass spectrometry (ICP-MS).

Microbial contamination is tested using cultivation methods or rapid techniques such as polymerase chain reaction (PCR). Degradation products and raw material stability are verified through accelerated stress tests, where the substance is exposed to elevated temperature, humidity, or light. The results of these tests must comply with the limits specified in pharmacopoeial monographs or the manufacturer's internal specifications. Exceeding these limits may lead to batch rejection or the need for further purification.

How to Ensure Proper Documentation and Compliance with Regulatory Requirements?

Documentation is an integral part of testing pharmaceutical raw materials and must be maintained in accordance with Good Manufacturing Practice (GMP) requirements. Each analysis must be thoroughly recorded, including the methods used, instruments, calibration standards, and results. Test protocols should also include data on method validation, personnel qualification, and regular equipment checks. These records serve as evidence for regulatory inspections and audit controls.

It is also important to monitor changes in legislation, such as updates to pharmacopoeias or REACH and CLP regulations. For example, newly identified impurities must be included in testing protocols, and their limits must be adjusted according to current requirements. To facilitate compliance, it is recommended to use specialized laboratory data management software (LIMS), which automates records and minimizes the risk of human error. Properly maintained documentation not only simplifies approval processes but also increases the confidence of customers and regulatory authorities in the quality of supplied raw materials.

Photo: Hans Reniers / Unsplash

What are the most common impurities in active pharmaceutical ingredients and how to identify them?

Active pharmaceutical ingredients (APIs) may contain various types of impurities, which are divided into several categories: organic impurities (residual solvents, synthesis intermediates), inorganic impurities (heavy metals, salts), and residual solvents. These impurities can originate from the manufacturing process, degradation of the raw material, or contamination during storage. Their presence can affect not only the efficacy of the drug but also its safety for patients. Therefore, it is crucial to not only detect impurities but also quantify them and compare them with limits set by regulatory authorities, such as the European Medicines Agency (EMA) or the U.S. Food and Drug Administration (FDA).

Combinations of analytical methods are used to identify impurities. Chromatographic techniques, such as HPLC (high-performance liquid chromatography) or GC (gas chromatography), enable the separation and quantification of individual components in a mixture. Mass spectrometry (MS) then provides detailed information about the structure of impurities. For inorganic impurities, atomic absorption spectrometry (AAS) or inductively coupled plasma mass spectrometry (ICP-MS) is often used. It is also important to verify whether impurities exceed the limits specified in pharmacopoeia monographs, such as the European Pharmacopoeia or USP.

How do storage and handling of APIs affect purity testing results?

Storage and handling of active pharmaceutical ingredients have a significant impact on their stability and, consequently, on purity testing results. Improper conditions, such as high temperature, humidity, or exposure to light, can lead to API degradation and the formation of new impurities. For example, some substances are sensitive to oxidation, while others are sensitive to hydrolysis, so it is necessary to adhere to the specific storage conditions specified in the technical documentation. It is recommended to store APIs in their original packaging, which provides protection against moisture and light, and in climate-controlled spaces with regulated temperature and humidity.

Handling of APIs should be carried out in accordance with Good Manufacturing Practice (GMP) rules. This includes using clean and appropriate tools, minimizing air exposure, and preventing cross-contamination. Before testing, it is important to thoroughly mix the sample to ensure its homogeneity. In the case of hygroscopic substances, it is necessary to work in a low-humidity environment to prevent water absorption and distortion of results. Adhering to these principles is crucial for obtaining reliable and reproducible testing results.

What are the challenges in validating analytical methods for testing pharmaceutical raw materials?

Validation of analytical methods is a necessary step to ensure the reliability and accuracy of purity and identity testing results for APIs. Key challenges include determining parameters such as specificity, linearity, precision, accuracy, robustness, and limits of detection and quantification. The specificity of the method must be verified to enable unambiguous identification of the target substance and its differentiation from potential impurities or matrix components. Linearity ensures that the method provides results proportional to the concentration of the analyte within a given range.

Another challenge is ensuring the robustness of the method, i.e., its ability to provide consistent results even with minor changes in conditions, such as temperature, pH, or mobile phase composition. Validation must be performed according to internationally recognized guidelines, such as ICH (International Council for Harmonisation), which define requirements for the validation of analytical methods for pharmaceutical purposes. Regular review and revalidation of methods are also important, particularly when changes occur in the manufacturing process or when new analytical technologies are introduced.

Do You Need Verified Pharmaceutical Raw Materials?

GCG Group supplies pharmaceutical raw materials with complete documentation, including analytical certificates and safety data sheets. Our experts will advise you on selecting suitable testing methods and ensure the raw materials meet strict GMP and other standards. Contact us – or browse our catalog of over 1,300 products right away.